{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:13:58Z","timestamp":1747167238263,"version":"3.40.5"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.mayocpiqo.2024.03.003","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T05:37:03Z","timestamp":1722145023000},"page":"407-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improving Patient Safety Through Proper Ordering and Administration of Andexanet Alfa"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2954-8849","authenticated-orcid":false,"given":"Krystof","family":"Stanek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad T.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron C.","family":"Spaulding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalmali","family":"Borkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8314-391X","authenticated-orcid":false,"given":"Marwan E.","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mayocpiqo.2024.03.003_bib4","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.mayocpiqo.2024.03.003_bib5","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.mayocpiqo.2024.03.003_bib6","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2024.03.003_bib7","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1160\/TH17-08-0553","article-title":"The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale","volume":"117","author":"Douketis","year":"2017","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2024.03.003_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1586\/17474086.2016.1135046","article-title":"Andexanet\u00a0alfa for the reversal of factor Xa inhibitor related anticoagulation","volume":"9","author":"Ghadimi","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2024.03.003_bib9","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A\u00a0specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.mayocpiqo.2024.03.003_bib11","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet\u00a0alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocpiqo.2024.03.003_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ajem.2022.02.036","article-title":"Andexanet\u00a0alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: a single-center, retrospective, matched cohort analysis","volume":"55","author":"Parsels","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2024.03.003_bib13","article-title":"Efficacy and safety of andexanet\u00a0alfa for bleeding caused by factor Xa inhibitors: a systematic review and meta-analysis","volume":"13","author":"Shrestha","year":"2021","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2024.03.003_bib14","doi-asserted-by":"crossref","first-page":"e1025","DOI":"10.1097\/CCM.0000000000005059","article-title":"Andexanet\u00a0alfa or prothrombin complex concentrate for factor Xa inhibitor reversal in acute major bleeding: a systematic review and meta-analysis","volume":"49","author":"Nederpelt","year":"2021","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2024.03.003_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000356","article-title":"Real-world observational review of andexanet\u00a0alfa prescribing and utilization outcomes at a community teaching hospital","volume":"3","author":"Sobolewski","year":"2021","journal-title":"Crit Care Explor"},{"key":"10.1016\/j.mayocpiqo.2024.03.003_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/10760296211039020","article-title":"Retrospective comparison of andexanet\u00a0alfa and 4-factor prothrombin complex for reversal of factor Xa-inhibitor related bleeding","volume":"27","author":"Stevens","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.mayocpiqo.2024.03.003_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ajem.2022.02.029","article-title":"Andexanet\u00a0alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages","volume":"55","author":"Pham","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.03.003_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11239-021-02495-3","article-title":"Andexanet\u00a0alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage","volume":"53","author":"Vestal","year":"2022","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2024.03.003_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11239-019-01973-z","article-title":"Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage","volume":"49","author":"Frontera","year":"2020","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2024.03.003_bib24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40264-013-0090-2","article-title":"Causes of medication administration errors in hospitals: a systematic review of quantitative and qualitative evidence","volume":"36","author":"Keers","year":"2013","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2024.03.003_bib25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2019000885","article-title":"A\u00a0phase 2 PK\/PD study of andexanet\u00a0alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers","volume":"4","author":"Lu","year":"2020","journal-title":"Blood Adv"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454824000134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454824000134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T18:41:46Z","timestamp":1723315306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454824000134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2542454824000134"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2024.03.003","relation":{},"ISSN":["2542-4548"],"issn-type":[{"type":"print","value":"2542-4548"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving Patient Safety Through Proper Ordering and Administration of Andexanet Alfa","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2024.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}